Neuropeptide Y (Npy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuropeptide Y (NPY) is a 36-amino acid peptide belonging to the NPY family of peptides, which also includes peptide YY (PYY) and pancreatic polypeptide (PP)[1]. Encoded by the NPY gene, this highly conserved peptide is one of the most abundant neuropeptides in the mammalian brain and acts as a powerful neuromodulator of stress responses, energy homeostasis, emotion, and synaptic plasticity. NPY exerts its effects through four G-protein coupled receptors (Y1, Y2, Y4, and Y5), making it a versatile signaling molecule with broad relevance to neurodegenerative disease research.
The NPY peptide adopts a characteristic PP-fold structure consisting of:
This three-dimensional structure is stabilized by interchain interactions and is shared across the NPY family[2].
NPY modulates synaptic transmission through pre- and post-synaptic mechanisms:
NPY is a potent orexigenic signal:
NPY modulates stress responses and emotional states:
NPY affects learning and memory:
NPY signals through four G-protein coupled receptors with distinct pharmacology:
| Receptor | Primary Coupling | Brain Distribution | Key Functions |
|---|---|---|---|
| Y1 (NPY1R) | Gi/o | Cortex, hippocampus, thalamus | Anxiety, feeding, memory |
| Y2 (NPY2R) | Gi/o | Hippocampus, hypothalamus | Presynaptic inhibition |
| Y4 (NPY4R) | Gi/o | Peripheral, limited CNS | Satiety |
| Y5 (NPY5R) | Gi/o | Hypothalamus, cortex | Feeding, seizures |
| Compound | Target | Development | Application |
|---|---|---|---|
| PYY3-36 | Y2/Y5 | Research | Obesity |
| BIIE0246 | Y2 | Preclinical | Anxiety |
| PF-5190457 | Y1 | Clinical | Obesity |
| CGP-71683 | Y5 | Preclinical | Obesity |
The study of Neuropeptide Y (Npy) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proceedings of the National Academy of Sciences. 1982;79(18):5485-5489. PMID:6812042.
Dion C, Jarvis P, Craig M, et al. Structural basis for NPY receptor interaction and drug discovery. Journal of Medicinal Chemistry. 2021;64(11):7434-7454. PMID:34029483.
Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Experimental Neurology. 2012;238(2):265-272. PMID:23022445.
Malva JO, Xapelli S, Baptista S, et al. Multifaces of neuropeptide Y in the brain - From neuroprotection to neuromodulation. Neuropeptides. 2012;46(6):299-308. PMID:23111051.
Heilig M. The NPY system in stress, anxiety and depression. Neuropharmacology. 2017;62(3):978-984. PMID:26476247.
Sah R, Geracioti TD. Neuropeptide Y and posttraumatic stress disorder. Progress in Neuropsychopharmacology & Biological Psychiatry. 2013;45:160-166. PMID:23541946.
Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian brain, exerting its effects through five Y receptor subtypes (Y1, Y2, Y3, Y4, Y5). Y1 and Y5 receptors are primarily responsible for the central effects of NPY on feeding, anxiety, and memory. These receptors couple to Gi/o proteins, inhibiting adenylate cyclase and reducing neuronal excitability through hyperpolarizing potassium currents.
NPY plays a crucial role in modulating synaptic transmission throughout the CNS. In the hippocampus, NPY inhibits glutamate release through presynaptic Y2 receptors, providing a neuroprotective mechanism against excitotoxicity. In the amygdala, NPY modulates anxiety-related behaviors through Y1 receptors in the basolateral complex.
Alzheimer's Disease: NPY is significantly altered in Alzheimer's disease, with decreased levels in certain brain regions. The peptide may play a role in regulating amyloid-beta toxicity, and Y1 receptor signaling has been implicated in neuroprotection. Some studies suggest NPY could serve as a biomarker for cognitive decline.
Parkinson's Disease: NPY neurons are affected in Parkinson's disease, particularly in the basal ganglia. The peptide modulates dopaminergic signaling and may influence motor complications such as dyskinesias. NPY expression is also altered in the striatum following dopaminergic denervation.
Huntington's Disease: NPY interneurons are selectively vulnerable in Huntington's disease, contributing to the characteristic motor and cognitive deficits. The loss of NPY-expressing striatal interneurons may disrupt inhibitory circuits and contribute to disease progression.
NPY receptor agonists, particularly Y2 and Y5 receptor-selective compounds, are being investigated for neurodegenerative disease applications. Y2 agonists may provide neuroprotection by reducing excitotoxicity, while Y5 antagonists have shown promise in animal models of cognitive enhancement.
Current studies are exploring NPY as a potential therapeutic target, with focus on developing brain-penetrant Y receptor modulators that can cross the blood-brain barrier. Gene therapy approaches to increase NPY expression are also being investigated.